Additionally, meta-analyses and a recent randomized controlled trial (RCT) study, which provide higher-level clinical evidence, consistently concluded that the use of PCSK9 inhibitors did not significantly affect all-cause HF [17–19]. The gene discussed is PCSK9; the disease is hydrops fetalis.